Study:
A Phase 1 Study of S-3304 in Patients With Solid Tumors
Rationale:
n/a
Purpose:
To determine the maximum tolerated dose and safety profile of S-3304 in patients with biopsy
accessible cancer who have failed previous therapy or to whom no standard therapies are
available. To determine the pharmacokinetic profile of S-3304 in this patient population
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Solid Tumors |
Drug: S-3304 |
Phase 1 |
Verified by
Shionogi
November, 2003
Sponsored by: Shionogi
Information provided by: Shionogi
ClinicalTrials.gov identifier: NCT00033215
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study
Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States
n/a